DuPont Reaffirms Outlook – Analyst Blog
Zacks Market Commentaries (November 9th, 2009) Writes:
On average, DuPont expects to deliver almost 20% year-over-year growth in earnings per share between 2009 and 2012. Despite an expected decline in pharmaceutical royalties after expiry of patents in 2010, DuPont expects to grow earnings between $2.10 and $2.40 per share in the year. The company has also reaffirmed its full-year 2009 earnings outlook of $1.95 to $2.05 per share, excluding significant items, which are estimated to be $0.15 per share for full-year 2009 or $1.80 to $1.90 per share on a reported basis. It had previously forecasted earnings of $1.70 to $2.10 a share. DuPont expects improving demand in key markets, as
...cent;, chemical, chemical makers, Dow Chemical Company, Dupont, DuPont Chemical Solutions Enterprise, energy, Investing Lessons, North America, pharmaceutical royalties, Protection Technologies, science-based products, Stocks to Watch, Titanium Technologies, USD, Zacks Market Commentaries


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
